Daawaynta Cusub ee Codsiga Dawooyinka ee Burooyinka Adag ee Sare

Written by editor

Nuvation Bio Inc. ayaa maanta ku dhawaaqday in Maamulka Cuntada iyo Dawooyinka ee Maraykanka (FDA) ay nadiifisay codsigeeda cusub ee baadhista (IND) si ay u qiimeeyaan NUV-868, BD2-xushay bromodomain afka yar yar iyo ka-hortagga-terminal (BET), daawaynta burooyinka adag ee horumarsan, oo ay ku jiraan kansarka ugxansidaha, kansarka ganaca, metastatic castration u adkeysiga kansarka qanjirka 'prostate' (mCRPC), iyo kansarka naasaha saddex-laaban (TNBC).

Print Friendly, PDF & Email

"Nafitaanka codsigayaga IND ee NUV-868 waa guul muhiim u ah Nuvation Bio maadaama ay calaamad u tahay IND afraad 14-kii bilood ee la soo dhaafay guud ahaan dhuumahayaga qoto dheer ee daaweynta kansarka cusub ee lagu beegsanayo noocyo badan oo burooyin ah," ayuu yiri David Hung, MD, aasaasaha. , madaxweynaha, iyo madaxa fulinta ee Nuvation Bio. "Waxaa na dhiirigeliyay xulashada iyo dulqaadka suurtagalka ah ee la wanaajiyey ee ay muujisay NUV-868 ee daraasadaha caafimaadka, waxaanan rajeyneynaa inaan u horumarino barnaamijka horumarinta Wajiga 1 ee bartamaha 2022."

NUV-868 waxay joojisaa BRD4, taas oo ah xubin muhiim ah oo ka tirsan qoyska BET oo si epigenetically u maamula borotiinnada xakameynaya koritaanka burada iyo kala duwanaanta. NUV-868 waxaa loogu talagalay inay noqoto mid door ah BD2 marka loo eego BD1 isku day lagu doonayo in laga fogaado xaddidaadda daweynta sunta kale ee BRD4 sida caloosha (GI) iyo sunta dhuuxa lafta. Daraasadaha hore ee bukaan-socodka ayaa muujiyay in NUV-868 ay ku dhawaad ​​​​1,500 jeer ka door bidaan BD2 marka loo eego BD1. Kahortagayaasha BD1/2 ee aan la dooran ee horumarinta ayaa lala xiriiriyay arrimaha dulqaadka, oo ay suurtagal tahay in ay ugu wacan tahay xannibaad badan oo BD1 ah.

Nadiifinta IND-kan NUV-868 ee burooyinka adag ee horumarsan, Nuvation Bio waxay bilaabi doontaa daraasadda wejiga 1/2 ee NUV-868 sida monotherapy oo ay weheliso olaparib ama enzalutamide ee noocyo badan oo burooyin ah. Hab-maamuuska (NUV-868-01) wuxuu ku bilaabmi doonaa wejiga 1 ee daraasadda kor u qaadida qiyaasta monotherapy ee bukaannada burada adag ee horumarsan. Daraasadda wejiga 1b ayaa markaa la bilaabi doonaa sahaminta NUV-868 oo ay weheliso olaparib ee kansarka ugxan-sidaha ee hore loo daaweeyay, kansarka ganaca, mCRPC, iyo bukaannada TNBC iyo marka lagu daro enzalutamide ee bukaannada mCRPC oo ay ku xigto daraasadda Wajiga 2b si loo sii sahamiyo badbaadada iyo waxtarka marka la go'aamiyo qiyaasta isku darka ee Wajiga 2 ee lagu taliyey. Daraasaadka monotherapy wejiga 2 ayaa sidoo kale lagu bilaabi doonaa bukaanada mCRPC iyo sidoo kale si loo sii sahamiyo badbaadada iyo waxtarka.

Print Friendly, PDF & Email

War ku saabsan qoraaga

editor

Tifaftiraha madaxa eTurboNew waa Linda Hohnholz. Waxay ku salaysan tahay eTN HQ ee Honolulu, Hawaii.

Leave a Comment